Announcements Trials
Browse Landscape

Phase

Phase 2 114Phase 1 51Phase 3 34Phase 1/2 30Phase NA 5Phase 2/3 4Phase EARLY_PHASE1 2Phase 4 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Neoplastic Cells, Circulating 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Magnetic Resonance Spectroscopy 61Cyclophosphamide 57pembrolizumab 39fludarabine 38Radiotherapy 30Nivolumab 30Biopsy 27Metformin 23Fluorodeoxyglucose F18 22Bevacizumab 22Specimen Handling 21Temozolomide 18Cisplatin 18Radiosurgery 17Carboplatin 16Fluorouracil 15Paclitaxel 14Dexamethasone 14Radiation 13Gemcitabine 13Etoposide 13Rituximab 12Positron Emission Tomography Computed Tomography 12Letrozole 12Irinotecan 12gallium 68 PSMA-11 11durvalumab 11atezolizumab 11X-Rays 11Surgical Procedures, Operative 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Interventional × osimertinib × Clear all
NCT03755102 2025-05-15

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Completed
17 enrolled
Thoracic

Lung Neoplasms

NCT06557096 2024-08-16

CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC

Second Affiliated Hospital of Nanchang University

Phase EARLY_PHASE1 Not yet recruiting
100 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplastic Cells, Circulating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡